Apogee Therapeutics Inc. (NASDAQ:APGE) Insider Sells $454,958.10 in Stock

Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total transaction of $454,958.10. Following the sale, the insider owned 238,998 shares of the company's stock, valued at approximately $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, June 4th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The shares were sold at an average price of $36.96, for a total value of $100,716.00.
• On Wednesday, May 7th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The shares were sold at an average price of $35.75, for a total transaction of $97,418.75.

Apogee Therapeutics Stock Performance

Shares of APGE traded up $3.23 during mid-day trading on Thursday, reaching $47.55. The stock had a trading volume of 507,962 shares, compared to its average volume of 563,959. The business has a fifty day moving average of $39.93 and a 200 day moving average of $39.10. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.24. Equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in APGE. New York State Common Retirement Fund raised its holdings in Apogee Therapeutics by 8.9% during the 4th quarter. New York State Common Retirement Fund now owns 12,187 shares of the company's stock valued at $552,000 after buying an additional 1,000 shares during the period. Aigen Investment Management LP bought a new position in Apogee Therapeutics during the fourth quarter valued at $216,000. Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 17.3% in the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company's stock valued at $295,000 after acquiring an additional 960 shares during the period. Swiss National Bank lifted its holdings in shares of Apogee Therapeutics by 17.5% in the 4th quarter. Swiss National Bank now owns 44,300 shares of the company's stock worth $2,007,000 after acquiring an additional 6,600 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Apogee Therapeutics in the 4th quarter worth about $1,099,000. Hedge funds and other institutional investors own 79.04% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on APGE shares. Citigroup assumed coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Finally, Guggenheim restated a "buy" rating and set a $116.00 target price on shares of Apogee Therapeutics in a report on Wednesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $95.80.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.